Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina

World Journal of Gastroenterology

Volumn 12, Issue 9, 2006, Pages 1426-1429

  Pérez, Luis Orlando ^a   Abba, Martin Carlos ^a   Dulout, Fernando Noel ^a   Golijow, Carlos Daniel ^a  

^a FACULTAD DE CIENCIAS VETERINARIAS   (Argentina)

Author keywords

Colorectal cancer; Human papilomavirus; p53 codon 72 polymorphism

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARGENTINA; ARTICLE; CITY; CODON; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PROTEIN FUNCTION; RECTUM CARCINOMA; STATISTICAL SIGNIFICANCE; WART VIRUS;

EID: 33645509089     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i9.1426     Document Type: Article

References (29)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004
2. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137: 603-612
3. Gazelle GS, McMahon PM, Scholz FJ. Screening for colorectal cancer. Radiology 2000; 215: 327-335
4. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004; 95: 7-11
5. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-100
6. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996; 17: 261-264
7. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11: 1684-1684
8. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004; 6: 529-535
9. Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004; 130: 728-732
10. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23: 1954-1956
11. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234
12. McGregor B, Byrne P, Kirgan D, Albright J, Manalo P, Hall M. Confirmation of the association of human papillomavirus with human colon cancer. Am J Surg 1993; 166: 738-740
13. Cheng JY, Sheu LF, Meng CL, Lee WH, Lin JC. Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut 1995; 37: 87-90
14. Lee YM, Leu SY, Chiang H, Fung CP, Liu WT. Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect 2001; 34: 87-91
15. Bodaghi S, Yamanegi K, Xiao SY, Da Costa M, Palefsky JM, Zheng ZM. Colorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res 2005; 11: 2862-2867
16. Perez LO, Abba MC, Laguens RM, Golijow CD. Analysis of adenocarcinoma of the colon and rectum: detection of human papillomavirus (HPV) DNA by polymerase chain reaction. Colorectal Dis 2005; 7: 492-495
17. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001; 109: 25-34
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
19. Abba MC, Villaverde LM, Gomez MA, Dulout FN, Laguens MR, Golijow CD. The p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol 2003; 109: 63-66
20. Evander M, Edlund K, Boden E, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G. Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol 1992; 30: 987-992
21. Golijow CD, Mouron SA, Gomez MA, Dulout FN. Differences in K-ras codon 12 mutation frequency between "high-risk" and "low-risk" HPV-infected samples. Gynecol Oncol 1999; 75: 108-112
22. Golijow CD, Abba M, Mouron SA, Gomez MA, Guercci A, Dulout FN. Detection of c-erbB-2 gene amplification in cervical scrapes positive for human papillomavirus (HPV). Cancer Invest 2001; 19: 678-683
23. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-270
24. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, Chakraborty R, Rothhammer F. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003; 36: 279-283
25. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11: 289-292
26. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, Zhang Y, Wang Y, Wen H. p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10: 2775-2778
27. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gustarson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47-54
28. Kaelin WG Jr. The emerging p53 gene family. J Natl Cancer Inst 1999; 91: 594-598
29. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 2003; 22: 5252-560